180 related articles for article (PubMed ID: 25456833)
41. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
42. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
43. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats.
Ma Y; Yang Q; Wang L; Zhou X; Zhao Y; Deng Y
Eur J Pharm Sci; 2012 Apr; 45(5):539-45. PubMed ID: 22155543
[TBL] [Abstract][Full Text] [Related]
44. Effect of the combined binding of topotecan and catechin/protocatechuic acid to a pH-sensitive DNA tetrahedron on release and cytotoxicity: Spectroscopic and calorimetric studies.
Wang L; Liu J; Wang X; Li X; Zhang X; Yuan L; Wu Y; Liu M
Spectrochim Acta A Mol Biomol Spectrosc; 2024 Jun; 314():124179. PubMed ID: 38522375
[TBL] [Abstract][Full Text] [Related]
45. Topotecan hydrochloride liposomes incorporated into thermosensitive hydrogel for sustained and efficient in situ therapy of H22 tumor in Kunming mice.
Xing J; Qi X; Jiang Y; Zhu X; Zhang Z; Qin X; Wu Z
Pharm Dev Technol; 2015 Nov; 20(7):812-819. PubMed ID: 24909735
[TBL] [Abstract][Full Text] [Related]
46. Interaction of clinically important human DNA topoisomerase I poison, topotecan, with double-stranded DNA.
Streltsov S; Oleinikov V; Ermishov M; Mochalov K; Sukhanova A; Nechipurenko Y; Grokhovsky S; Zhuze A; Pluot M; Nabiev I
Biopolymers; 2003; 72(6):442-54. PubMed ID: 14587067
[TBL] [Abstract][Full Text] [Related]
47. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release.
Souza LG; Silva EJ; Martins AL; Mota MF; Braga RC; Lima EM; Valadares MC; Taveira SF; Marreto RN
Eur J Pharm Biopharm; 2011 Sep; 79(1):189-96. PubMed ID: 21352915
[TBL] [Abstract][Full Text] [Related]
48. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
Ma J; Maliepaard M; Nooter K; Loos WJ; Kolker HJ; Verweij J; Stoter G; Schellens JH
Br J Cancer; 1998 May; 77(10):1645-52. PubMed ID: 9635842
[TBL] [Abstract][Full Text] [Related]
49. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.
Taron M; Plasencia C; Abad A; Martin C; Guillot M
Invest New Drugs; 2000 May; 18(2):139-47. PubMed ID: 10857993
[TBL] [Abstract][Full Text] [Related]
50. Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours.
Centelles MN; Wright M; So PW; Amrahli M; Xu XY; Stebbing J; Miller AD; Gedroyc W; Thanou M
J Control Release; 2018 Jun; 280():87-98. PubMed ID: 29723616
[TBL] [Abstract][Full Text] [Related]
51. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches.
Pan P; Li Y; Yu H; Sun H; Hou T
J Chem Inf Model; 2013 Apr; 53(4):997-1006. PubMed ID: 23521602
[TBL] [Abstract][Full Text] [Related]
52. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
Yamashita Y; Krauze MT; Kawaguchi T; Noble CO; Drummond DC; Park JW; Bankiewicz KS
Neuro Oncol; 2007 Jan; 9(1):20-8. PubMed ID: 17018695
[TBL] [Abstract][Full Text] [Related]
53. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
[TBL] [Abstract][Full Text] [Related]
54. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
55. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
56. Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.
Zhang JL; Sharma PL; Li CJ; Dezube BJ; Pardee AB; Crumpacker CS
Antimicrob Agents Chemother; 1997 May; 41(5):977-81. PubMed ID: 9145855
[TBL] [Abstract][Full Text] [Related]
57. Topotecan Alleviates Lipopolysaccharide-Mediated Acute Lung Injury Via the NF-κB Signaling Pathway.
Jin J; Xu W; Wan B; Wang X; Zhou Z; Miao Y; Lv T; Song Y
J Surg Res; 2019 Mar; 235():83-92. PubMed ID: 30691855
[TBL] [Abstract][Full Text] [Related]
58. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
59. Synergistic effect of combination topotecan and chronomodulated radiation therapy on xenografted human nasopharyngeal carcinoma.
Zhang Y; Chen X; Ren P; Su Z; Cao H; Zhou J; Zou X; Fu S; Lin S; Fan J; Yang B; Sun X; Zhou Y; Chen Y; Yang L; Wu J
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):356-62. PubMed ID: 23906928
[TBL] [Abstract][Full Text] [Related]
60. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Lamond JP; Wang M; Kinsella TJ; Boothman DA
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):361-8. PubMed ID: 8892461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]